OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility | Zendy

Maria E. Cabanillas | Zendy; Naifa L. Busaidy | Zendy; Ramona Dadu | Zendy; Renata Ferrarotto | Zendy; Neil D. Gross | Zendy; Maria Gule-Monroe | Zendy; Charles Lu | Zendy; Horiana B. Grosu | Zendy; Michelle D. Williams | Zendy; Mark Zafereo | Zendy

Open Access

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility

Author(s) -

Maria E. Cabanillas,

Naifa L. Busaidy,

Ramona Dadu,

Renata Ferrarotto,

Neil D. Gross,

Maria Gule-Monroe,

Charles Lu,

Horiana B. Grosu,

Michelle D. Williams,

Mark Zafereo

Publication year - 2019

Publication title -

journal of the endocrine society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.046

H-Index - 20

ISSN - 2472-1972

DOI - 10.1210/js.2019-or27-6

Subject(s) - medicine , vemurafenib , trametinib , cohort , dabrafenib , atezolizumab , oncology , everolimus , mek inhibitor , regimen , kras , anaplastic thyroid cancer , thyroid cancer , surgery , cancer , colorectal cancer , pembrolizumab , kinase , immunotherapy , mapk/erk pathway , metastatic melanoma , biology , microbiology and biotechnology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research